Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 360 Shares

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 360 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $34.90, for a total value of $12,564.00. Following the completion of the transaction, the insider directly owned 286,516 shares in the company, valued at $9,999,408.40. This represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rapport Therapeutics Trading Up 1.7%

Shares of RAPP stock traded up $0.57 during mid-day trading on Thursday, reaching $34.26. The stock had a trading volume of 198,238 shares, compared to its average volume of 331,640. The business’s fifty day moving average is $28.98 and its 200-day moving average is $28.10. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -11.98 and a beta of 1.09. Rapport Therapeutics, Inc. has a 1-year low of $7.73 and a 1-year high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). On average, analysts forecast that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. BTIG Research increased their price objective on Rapport Therapeutics to $47.00 and gave the company a “buy” rating in a report on Monday, March 9th. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, March 10th. Truist Financial raised Rapport Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Institutional Trading of Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital International Investors grew its holdings in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after acquiring an additional 800,000 shares during the period. Goldman Sachs Group Inc. grew its holdings in Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock worth $91,077,000 after acquiring an additional 579,903 shares during the period. Vanguard Group Inc. grew its holdings in Rapport Therapeutics by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after acquiring an additional 191,219 shares during the period. Baker BROS. Advisors LP grew its holdings in Rapport Therapeutics by 181.2% during the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock worth $45,949,000 after acquiring an additional 997,000 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in Rapport Therapeutics by 4.1% during the second quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company’s stock worth $13,129,000 after acquiring an additional 45,063 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.